CID-103 Treatment for Kidney Transplant Rejection
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- Your transplanted kidney must be working for at least 6 months
- You have antibodies attacking your transplant (confirmed by blood tests and kidney biopsy)
- Your kidney function is at least moderate (eGFR ≥ 25)
- You must be willing to have a kidney biopsy within 4 weeks of starting treatment
- You cannot have active infections, certain cancers, or severe other diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This trial tests a new drug called SG301 for people whose kidney transplant is being rejected by their own antibodies (antibody-mediated rejection, or AMR). The drug targets a protein on antibody-producing cells to help stop the rejection and protect the transplanted kidney.
This trial tests whether giving a special type of umbilical cord cell can help treat a form of kidney rejection that hasn't improved with standard antibody treatment. It aims to slow down or stop further kidney damage.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This study tests a new medicine called mezagitamab for people whose kidney transplant is being rejected by their immune system (a condition called antibody-mediated rejection). The goal is to see if it can help stop the rejection and protect the transplanted kidney.
Hear when a new Antibody-mediated Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.